Oncology · Cognitive ImpairmentTrial Updateclinicalmid-term

Phase 2a Trial of Riluzole for Cancer-Related Cognitive Impairment Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/17/2026, 6:32:13 AM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of a phase 2a trial for riluzole in treating cognitive impairment in cancer survivors is significant as it explores a novel therapeutic avenue in a largely underserved area. Positive outcomes could enhance riluzole's market positioning and broaden its clinical applications, impacting treatment paradigms in oncology. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (16 high-relevance).

Strategic Assessment

Success in this trial may open new avenues for riluzole's use beyond its current indications, impacting treatment strategies for cognitive deficits in oncology. The strongest clinical anchor is Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial (ClinicalTrials.gov), entity match (riluzole). In Oncology · Cognitive Impairment, 5 regulatory and 4 competitive items passed relevance filtering for Riluzole.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial could position riluzole as a potential treatment for cognitive impairment in cancer patients, an area with limited therapeutic options.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (indication). Relevant agencies in corpus: FDA, MHRA. The trial's results could influence future regulatory submissions for riluzole's use in cognitive impairment, potentially leading to new indications and label expansions.

Key Risks

Elevated medium regulatory exposure for Riluzole could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Riluzole through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If successful, riluzole could capture a new segment of the oncology market, potentially increasing revenue streams and market share in a niche but critical area of patient care.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and BDNF level changes, as well as any subsequent studies or interest from other companies in this indication.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
ClinicalTrials.govhigh relevance
Entity match (riluzole)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Traditional Chinese Medicine Patch for Cancer-Related Fatigue During Radiotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Barriers to satisfactory primary care contacts for Swedish cancer survivors: a cross-sectional survey.
PubMedhigh relevance
Entity match (cancer survivors)
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Riluzole
cancer survivors

Commercial impact

medium

If successful, riluzole could capture a new segment of the oncology market, potentially increasing revenue streams and market share in a niche but critical area of patient care.

Regulatory impact

medium

The trial's results could influence future regulatory submissions for riluzole's use in cognitive impairment, potentially leading to new indications and label expansions.

What to watch

Monitor trial results and BDNF level changes, as well as any subsequent studies or interest from other companies in this indication.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.